Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Illustration: Eniola Odetunde/Axios
The German government will invest €300 million for a 23% ownership stake in CureVac, a VC-backed mRNA biotech working on a COVID-19 vaccine.
Why it matters: The deal is intended to prevent CureVac from relocating or being acquired by a foreign investor, reflecting increased global protectionism around coronavirus drugs.
The backdrop: In March, a German newspaper reported that the Trump administration had discussed buying CureVac, sparking outrage in Germany.
- CureVac is majority-owned owned by SAP co-founder Dietmar Hopp, via his VC firm, while other backers include Eli Lilly, Baillie Gifford, and the Bill & Melinda Gates Foundation.
The bottom line: "It's not clear whether Germany will seek to gain preferential access to the [CureVac] vaccine should it come through testing." — Ben Adams, FierceBiotech
Go deeper: Moderna reveals the limits of making a coronavirus vaccine